Timothy Y Y Lai Selected Research

Verteporfin (Visudyne)

2/2021	RANIBIZUMAB WITH OR WITHOUT VERTEPORFIN PHOTODYNAMIC THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: Predictors of Visual and Anatomical Response in the EVEREST II Study.
1/2020	Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: The EVEREST II Randomized Clinical Trial.
10/2019	RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN ASIAN PATIENTS WITH MYOPIC CHOROIDAL NEOVASCULARIZATION: BRILLIANCE, a 12-Month, Randomized, Double-Masked Study.
11/2017	Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
1/2015	Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).
9/2011	Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.
7/2011	Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial.
2/2010	Photodynamic therapy with or without intravitreal triamcinolone acetonide for symptomatic polypoidal choroidal vasculopathy.
10/2008	Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
1/2008	Combined photodynamic therapy and intravitreal triamcinolone for choroidal neovascularization secondary to punctate inner choroidopathy or of idiopathic origin: one-year results of a prospective series.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Timothy Y Y Lai Research Topics

Disease

27	Macular Degeneration (Age-Related Maculopathy) 01/2022 - 03/2006
24	Choroidal Neovascularization 01/2022 - 09/2003
23	Polypoidal Choroidal Vasculopathy 10/2021 - 08/2004
8	Myopia 12/2020 - 03/2006
8	Macular Edema 01/2018 - 09/2003
7	Central Serous Chorioretinopathy 01/2015 - 11/2003
6	Atrophy 01/2022 - 03/2002
6	Hemorrhage 12/2018 - 09/2003
6	Cataract (Cataracts) 01/2018 - 12/2002
5	Retinal Perforations 04/2010 - 03/2002
4	Retinal Detachment (Retinal Detachments) 01/2022 - 03/2002
4	Anterior Uveitis 11/2013 - 12/2009
4	Epiretinal Membrane (Epiretinal Membranes) 02/2009 - 10/2003
3	White Dot Syndromes 01/2018 - 06/2007
3	Polyps 11/2017 - 08/2004
3	Glaucoma 07/2015 - 12/2002
2	COVID-19 07/2020 - 03/2020
2	Vision Disorders (Hemeralopia) 10/2019 - 07/2015
2	Uveitis 07/2019 - 01/2018
2	Retinal Vein Occlusion 01/2018 - 09/2003
2	Fibrosis (Cirrhosis) 01/2018 - 06/2012
2	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2017 - 09/2016
2	Bietti Crystalline Dystrophy 07/2016 - 02/2010
2	Ischemia 07/2015 - 06/2012
2	Osteoma 01/2014 - 05/2012
2	Open-Angle Glaucoma (Glaucoma, Open Angle) 02/2009 - 01/2006
1	Cysts 11/2021
1	Vascular Diseases (Vascular Disease) 01/2021
1	Retinal Vasculitis 07/2019
1	Behcet Syndrome (Behcet's Syndrome) 07/2019
1	Retinitis Pigmentosa (Pigmentary Retinopathy) 01/2017
1	Disease Progression 01/2017
1	Ganglion Cysts (Ganglion) 01/2017
1	Cicatrix (Scar) 12/2015
1	Vitreous Hemorrhage 12/2015
1	Endophthalmitis (Ophthalmia) 11/2015
1	Retinal Diseases 10/2013
1	Optic Neuritis (Retrobulbar Neuritis) 01/2013
1	Vasculitis (Vasculitides) 06/2012
1	Posterior Uveitis 01/2012
1	Blepharitis 09/2011
1	Infections 09/2011
1	Retinitis 03/2011
1	Acquired Immunodeficiency Syndrome (AIDS) 03/2011

Drug/Important Bio-Agent (IBA)

22	Retinaldehyde (Retinal)IBA 11/2021 - 03/2002
21	Ranibizumab (Lucentis)FDA Link 07/2021 - 08/2007
16	Verteporfin (Visudyne)FDA Link 02/2021 - 09/2003
11	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 03/2006
11	1-phenyl-3,3-dimethyltriazene (PDT)IBA 10/2021 - 11/2003
7	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2021 - 12/2003
6	Bevacizumab (Avastin)FDA Link 04/2012 - 06/2007
4	Complement Factor H (Factor H)IBA 11/2013 - 01/2011
4	Triamcinolone (Aristocort)FDA Link 04/2012 - 02/2007
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2019 - 10/2009
3	Fluorescein (Funduscein)FDA LinkGeneric 09/2011 - 09/2003
2	Endothelial Growth FactorsIBA 01/2021 - 01/2014
2	Chloroquine (Aralen)FDA LinkGeneric 07/2020 - 03/2020
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 07/2020 - 03/2020
2	Prostaglandins FIBA 10/2019 - 04/2016
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2018 - 01/2013
2	salicylhydroxamic acid (SHAM)IBA 01/2018 - 01/2018
2	Complement C1 Inhibitor Protein (C1 Esterase Inhibitor)IBA 03/2015 - 11/2013
2	Retinal Pigments (Pigments, Visual)IBA 06/2012 - 08/2007
2	Interleukin-27 (Interleukin 27)IBA 01/2012 - 01/2011
2	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 02/2010 - 12/2007
2	pigment epithelium-derived factorIBA 10/2008 - 03/2006
1	faricimabIBA 01/2022
1	AngiopoietinsIBA 01/2021
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	Adalimumab (Humira)FDA Link 07/2019
1	afliberceptIBA 03/2019
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Angiopoietin-2IBA 01/2017
1	Adenosine Triphosphate (ATP)IBA 10/2016
1	Biological ProductsIBA 04/2016
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2015
1	Povidone-Iodine (Betadine)FDA LinkGeneric 11/2015
1	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 07/2015
1	Neuroprotective AgentsIBA 07/2015
1	Complement C3 (C3 Complement)IBA 11/2014
1	HDL LipoproteinsIBA 04/2014
1	Complement C1 (Complement 1)IBA 11/2013
1	Immunomodulating AgentsIBA 01/2013
1	Pharmaceutical PreparationsIBA 03/2012
1	InterleukinsIBA 01/2012
1	Indicators and Reagents (Reagents)IBA 03/2011

Therapy/Procedure

18	Photochemotherapy (Photodynamic Therapy) 10/2021 - 09/2003
10	Therapeutics 01/2022 - 03/2002
9	Lasers (Laser) 07/2015 - 09/2003
7	Injections 11/2017 - 08/2007
5	Intravitreal Injections 01/2016 - 08/2007
4	Light Coagulation 04/2012 - 09/2003
4	Vitrectomy 02/2009 - 03/2002
2	Traction 01/2022 - 01/2021
2	Vitreoretinal Surgery 01/2021 - 01/2016
2	Phacoemulsification 01/2007 - 09/2006
1	Drug Therapy (Chemotherapy) 01/2018
1	Contact Lenses 09/2011
1	Highly Active Antiretroviral Therapy (HAART) 03/2011